Dana Penik, NP
Family · Glenville, NYNPI 1184021750
Payments from drug & device makers
Across 112 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$482
- GSK$290
- AbbVie$253
- Pfizer$102
- Lilly USA, LLC$93
- Biohaven Pharmaceuticals, Inc.$81
- plus $809 from 21 others
What the payments were for
- Food & beverage$2,110100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $482 |
| GSK | 17 | $290 |
| AbbVie | 14 | $253 |
| Pfizer | 5 | $102 |
| Lilly USA, LLC | 5 | $93 |
| Biohaven Pharmaceuticals, Inc. | 5 | $81 |
| AstraZeneca | 5 | $77 |
| Boehringer Ingelheim | 3 | $73 |
| Otsuka America Pharmaceutical, Inc. | 4 | $63 |
| Amgen | 3 | $58 |
| Exact Sciences | 2 | $52 |
| Renalytix AI, Inc. | 3 | $49 |
| Abbott | 2 | $47 |
| Edwards Lifesciences | 2 | $45 |
| Bayer | 2 | $45 |
| Novartis | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Vertex | 1 | $32 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Eisai Inc. | 1 | $25 |
| Merck | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Verona Pharma, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Gilead | 1 | $18 |
| Boston Scientific | 1 | $15 |
How this compares
$2,110 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $55,321 |
| EliquisApixaban | 50 | $37,339 |
| OzempicSemaglutide | 31 | $33,676 |
| JanuviaSitagliptin Phosphate | 34 | $24,049 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $15,341 |
| FarxigaDapagliflozin Propanediol | 17 | $13,235 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,593 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,425 |
| Varenicline Tartrate | 13 | $3,354 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,911 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $2,336 |
| Atorvastatin Calcium | 230 | $2,177 |
| Pravastatin Sodium | 120 | $2,033 |
| Levothyroxine Sodium | 233 | $1,922 |
| Novolog FlexpenInsulin Aspart | 11 | $1,671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $73 | $55,32158 claims |
| PfizerEliquis | $102 | $37,33950 claims |
| Novo NordiskOzempic | $482 | $33,67631 claims |
| MerckJanuvia | $24 | $24,04934 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $290 | $19,93426 claims |
| AstraZenecaFarxiga | $77 | $13,23517 claims |
| AbbVieSynthroid | $253 | $94714 claims |
| Lilly USA, LLCHumalog | $93 | $74412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.
Other family in Glenville
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.